• 1 a Pharmacology Research Laboratory, Institute of Pharmacy , Nirma University , Ahmedabad , India
  • 2 b Pharmaceutical Nanotechnology Research Laboratory , Adina Institute of Pharmaceutical Sciences , Sagar , India
  • 3 c Faculty of Pharmacy, Centre for Drug Delivery Research , Universiti Kebangsaan Malaysia , Kuala Lumpur , Malaysia
  • 4 d Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences , Wayne State University , Detroit , MI , USA
  • 5 e Department of Pharmaceutical Technology , School of Pharmacy , The International Medical University , Jalan Jalil Perkasa, Kuala Lumpur , Malaysia
J Biomater Sci Polym Ed, 2016 May;27(7):557-80.
PMID: 26928261 DOI: 10.1080/09205063.2015.1133155


Worldwide, the cancer appeared as one of the most leading cause of morbidity and mortality. Among the various cancer types, brain tumors are most life threatening with low survival rate. Every year approximately 238,000 new cases of brain and other central nervous system tumors are diagnosed. The dendrimeric approaches have a huge potential for diagnosis and treatment of brain tumor with targeting abilities of molecular cargoes to the tumor sites and the efficiency of crossing the blood brain barrier and penetration to brain after systemic administration. The various generations of dendrimers have been designed as novel targeted drug delivery tools for new therapies including sustained drug release, gene therapy, and antiangiogenic activities. At present era, various types of dendrimers like PAMAM, PPI, and PLL dendrimers validated them as milestones for the treatment and diagnosis of brain tumor as well as other cancers. This review highlights the recent research, opportunities, advantages, and challenges involved in development of novel dendrimeric complex for the therapy of brain tumor.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.